Autoimmune diseases and reproductive aging

Clinical Immunology

Volumn 149, Issue 2, 2013, Pages 251-264

  Bove, Riley ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Andropause; ; Hormone replacement therapy; Menopause; ; Multiple sclerosis; ; Rheumatoid arthritis; ; Systemic lupus erythematosus;

Indexed keywords

ANDROGEN; ANDROSTANOLONE; CORTICOSTEROID; CYCLOSPORIN A; ESTRADIOL; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRASTERONE; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

ACNE; AGING; ANDROGEN THERAPY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLIMACTERIUM; DISEASE ACTIVITY; DISEASE COURSE; ENDOCRINE DISEASE; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; HYPOANDROGENISM; MENOPAUSE; MULTIPLE SCLEROSIS; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TESTOSTERONE BLOOD LEVEL; THROMBOEMBOLISM;

ANDROPAUSE;; HORMONE REPLACEMENT THERAPY; MENOPAUSE;; MULTIPLE SCLEROSIS;; RHEUMATOID ARTHRITIS;; SYSTEMIC LUPUS ERYTHEMATOSUS;;

AGING; ANDROGENS; AUTOIMMUNE DISEASES; FEMALE; HUMANS; MALE; MENOPAUSE; REPRODUCTION;

EID: 84885957916     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.02.010     Document Type: Review

References (125)

1. Cutolo M., Sulli A., Giusti M., Barone A., Seriolo B., Accardo S. Increase in serum 5 alpha-androstane-3 alpha,17 beta-diol glucuronide as a possible marker of the androgen-mediated immunosuppressive activity exerted by cyclosporin A: preliminary results. Clin. Exp. Rheumatol. 1994, 12:350-351.
2. Sulli A., Pizzorni C., Scotto-Busato R., Accardo S., Cutolo M. Androgenizing effects of cyclosporin A in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1999, 876:391-396.
3. Giltay E.J., van den Borne B.E., van Schaardenburg D., Gooren L.J., Popp-Snijders C., Blankenstein M.A., Dijkmans B.A. Androgenizing effects of low-dose cyclosporin in male patients with early RA. Br. J. Rheumatol. 1998, 37:470-472.
4. Cutolo M., Sulli A., Craviotto C., Felli L., Pizzorni C., Seriolo B., Villaggio B. Antiproliferative-antiinflammatory effects of methotrexate and sex hormones on cultured differentiating myeloid monocytic cells (THP-1). Ann. N. Y. Acad. Sci. 2002, 966:232-237.
5. Gold S.M., Voskuhl R.R. Estrogen and testosterone therapies in multiple sclerosis. Prog. Brain Res. 2009, 175:239-251.
6. Ganesan K., Balachandran C., Manohar B.M., Puvanakrishnan R. Comparative studies on the interplay of testosterone, estrogen and progesterone in collagen induced arthritis in rats. Bone 2008, 43:758-765.
7. Panchanathan R., Shen H., Bupp M.G., Gould K.A., Choubey D. Female and male sex hormones differentially regulate expression of Ifi202, an interferon-inducible lupus susceptibility gene within the Nba2 interval. J. Immunol. 2009, 183:7031-7038.
8. Bebo B.F., Zelinka-Vincent E., Adamus G., Amundson D., Vandenbark A.A., Offner H. Gonadal hormones influence the immune response to PLP 139-151 and the clinical course of relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1998, 84:122-130.
9. Fillmore P.D., Blankenhorn E.P., Zachary J.F., Teuscher C. Adult gonadal hormones selectively regulate sexually dimorphic quantitative traits observed in experimental allergic encephalomyelitis. Am. J. Pathol. 2004, 164:167-175.
10. Ganesan K., Selvam R., Abhirami R., Raju K.V., Manohar B.M., Puvanakrishnan R. Gender differences and protective effects of testosterone in collagen induced arthritis in rats. Rheumatol. Int. 2008, 28:345-353.
11. Palaszynski K.M., Loo K.K., Ashouri J.F., Liu H.B., Voskuhl R.R. Androgens are protective in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J. Neuroimmunol. 2004, 146:144-152.
12. Maccio D.R., Calfa G., Roth G.A. Oral testosterone in male rats and the development of experimental autoimmune encephalomyelitis. Neuroimmunomodulation 2005, 12:246-254.
13. Jimenez-Balderas F.J., Tapia-Serrano R., Fonseca M.E., Arellano J., Beltran A., Yanez P., Camargo-Coronel A., Fraga A. High frequency of association of rheumatic/autoimmune diseases and untreated male hypogonadism with severe testicular dysfunction. Arthritis Res. 2001, 3:362-367.
14. Inman R.D., Jovanovic L., Markenson J.A., Longcope C., Dawood M.Y., Lockshin M.D. Systemic lupus erythematosus in men. Genetic and endocrine features. Arch. Intern. Med. 1982, 142:1813-1815.
15. Miller M.H., Urowitz M.B., Gladman D.D., Killinger D.W. Systemic lupus erythematosus in males. Medicine (Baltimore) 1983, 62:327-334.
16. Carrabba M., Giovine C., Chevallard M., Angelini M., Ambrosi B., Travaglini P. Abnormalities of sex hormones in men with systemic lupus erythematosus. Clin. Rheumatol. 1985, 4:420-425.
17. Folomeev M., Dougados M., Beaune J., Kouyoumdjian J.C., Nahoul K., Amor B., Alekberova Z. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus 1992, 1:191-195.
18. Sequeira J.F., Keser G., Greenstein B., Wheeler M.J., Duarte P.C., Khamashta M.A., Hughes G.R. Systemic lupus erythematosus: sex hormones in male patients. Lupus 1993, 2:315-317.
19. Vilarinho S.T., Costallat L.T. Evaluation of the hypothalamic-pituitary-gonadal axis in males with systemic lupus erythematosus. J. Rheumatol. 1998, 25:1097-1103.
20. Chang D.M., Chang C.C., Kuo S.Y., Chu S.J., Chang M.L. Hormonal profiles and immunological studies of male lupus in Taiwan. Clin. Rheumatol. 1999, 18:158-162.
21. Mok C.C., Lau C.S. Profile of sex hormones in male patients with systemic lupus erythematosus. Lupus 2000, 9:252-257.
22. Bhattoa H.P., Kiss E., Bettembuk P., Balogh A. Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus. Rheumatol. Int. 2001, 21:97-102.
23. Vecchi A.P., Borba E.F., Bonfa E., Cocuzza M., Pieri P., Kim C.A., Silva C.A. Penile anthropometry in systemic lupus erythematosus patients. Lupus 2011, 20:512-518.
24. Gordon D., Beastall G.H., Thomson J.A., Sturrock R.D. Prolonged hypogonadism in male patients with rheumatoid arthritis during flares in disease activity. Br. J. Rheumatol. 1988, 27:440-444.
25. Cutolo M., Balleari E., Giusti M., Monachesi M., Accardo S. Sex hormone status of male patients with rheumatoid arthritis: evidence of low serum concentrations of testosterone at baseline and after human chorionic gonadotropin stimulation. Arthritis Rheum. 1988, 31:1314-1317.
26. Spector T.D., Ollier W., Perry L.A., Silman A.J., Thompson P.W., Edwards A. Free and serum testosterone levels in 276 males: a comparative study of rheumatoid arthritis, ankylosing spondylitis and healthy controls. Clin. Rheumatol. 1989, 8:37-41.
27. Martens H.F., Sheets P.K., Tenover J.S., Dugowson C.E., Bremner W.J., Starkebaum G. Decreased testosterone levels in men with rheumatoid arthritis: effect of low dose prednisone therapy. J. Rheumatol. 1994, 21:1427-1431.
28. Masi A.T. Sex hormones and rheumatoid arthritis: cause or effect relationships in a complex pathophysiology?. Clin. Exp. Rheumatol. 1995, 13:227-240.
29. Masi A.T., Feigenbaum S.L., Chatterton R.T. Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. Semin. Arthritis Rheum. 1995, 25:1-27.
30. Kanik K.S., Chrousos G.P., Schumacher H.R., Crane M.L., Yarboro C.H., Wilder R.L. Adrenocorticotropin, glucocorticoid, and androgen secretion in patients with new onset synovitis/rheumatoid arthritis: relations with indices of inflammation. J. Clin. Endocrinol. Metab. 2000, 85:1461-1466.
31. Straub R.H., Paimela L., Peltomaa R., Scholmerich J., Leirisalo-Repo M. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum. 2002, 46:654-662.
32. Ernestam S., Hafstrom I., Werner S., Carlstrom K., Tengstrand B. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function. J. Rheumatol. 2007, 34:1451-1458.
33. Tengstrand B., Carlstrom K., Hafstrom I. Gonadal hormones in men with rheumatoid arthritis-from onset through 2years. J. Rheumatol. 2009, 36:887-892.
34. Tengstrand B., Carlstrom K., Hafstrom I. Bioavailable testosterone in men with rheumatoid arthritis-high frequency of hypogonadism. Rheumatology 2002, 41:285-289.
35. Wei T., Lightman S.L. The neuroendocrine axis in patients with multiple sclerosis. Brain 1997, 120(Pt 6):1067-1076.
36. Foster S.C., Daniels C., Bourdette D.N., Bebo B.F. Dysregulation of the hypothalamic-pituitary-gonadal axis in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Neuroimmunol. 2003, 140:78-87.
37. Tomassini V., Onesti E., Mainero C., Giugni E., Paolillo A., Salvetti M., Nicoletti F., Pozzilli C. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J. Neurol. Neurosurg. Psychiatry 2005, 76:272-275.
38. Safarinejad M.R. Evaluation of endocrine profile, hypothalamic-pituitary-testis axis and semen quality in multiple sclerosis. J. Neuroendocrinol. 2008, 20:1368-1375.
39. Straub R.H., Weidler C., Demmel B., Herrmann M., Kees F., Schmidt M., Scholmerich J., Schedel J. Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus. Ann. Rheum. Dis. 2004, 63:961-968.
40. Pines A. Male menopause: is it a real clinical syndrome?. Climacteric 2011, 14:15-17.
41. Vermeulen A. Declining androgens with age: an overview. Androgens and the aging male 1996, 3-14. Parthenon Publishing, New York. A. Vermeulen, B.J. Oddens (Eds.).
42. Gould D.C., Petty R., Jacobs H.S. For and against: the male menopause-does it exist?. BMJ 2000, 320:858-861.
43. Watkins E.S. The medicalisation of male menopause in America. Soc. Hist. Med. 2007, 20:369-388.
44. Tengstrand B., Ahlmen M., Hafstrom I. The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2years. J. Rheumatol. 2004, 31:214-222.
45. Tengstrand B., Hafstrom I. Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. J. Rheumatol. 2002, 29:2299-2305.
46. Gordon C., Wallace D.J., Shinada S., Kalunian K.C., Forbess L., Braunstein G.D., Weisman M.H. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. Rheumatology 2008, 47:334-338.
47. Petri M.A., Mease P.J., Merrill J.T., Lahita R.G., Iannini M.J., Yocum D.E., Ginzler E.M., Katz R.S., Gluck O.S., Genovese M.C., Van Vollenhoven R., Kalunian K.C., Manzi S., Greenwald M.W., Buyon J.P., Olsen N.J., Schiff M.H., Kavanaugh A.F., Caldwell J.R., Ramsey-Goldman R., St Clair E.W., Goldman A.L., Egan R.M., Polisson R.P., Moder K.G., Rothfield N.F., Spencer R.T., Hobbs K., Fessler B.J., Calabrese L.H., Moreland L.W., Cohen S.B., Quarles B.J., Strand V., Gurwith M., Schwartz K.E. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004, 50:2858-2868.
48. van Vollenhoven R.F., Morabito L.M., Engleman E.G., McGuire J.L. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12months. J. Rheumatol. 1998, 25:285-289.
49. Chang D.M., Lan J.L., Lin H.Y., Luo S.F. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46:2924-2927.
50. Crosbie D., Black C., McIntyre L., Royle P.L., Thomas S. Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database Syst. Rev. 2007, CD005114.
51. Cutolo M., Balleari E., Giusti M., Intra E., Accardo S. Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum. 1991, 34:1-5.
52. Hall G.M., Larbre J.P., Spector T.D., Perry L.A., Da Silva J.A. A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br. J. Rheumatol. 1996, 35:568-573.
53. Margolis H.M., Caplan P.S. The effect of some steroids (testosterone propionate, desoxycorticosterone acetate and ascorbic acid, and 21-acetoxy delta-5-pregnenolone, artisone acetate, Wyeth) in rheumatoid arthritis. Ann. Intern. Med. 1951, 34:61-71.
54. Booji A., Biewenga-Booji C.M., Huber-Bruning O., Cornelis C., Jacobs J.W., Bijlsma J.W. Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis. Ann. Rheum. Dis. 1996, 55:811-815.
55. Straub R.H., Harle P., Yamana S., Matsuda T., Takasugi K., Kishimoto T., Nishimoto N. Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2006, 54:1778-1785.
56. Sicotte N.L., Giesser B.S., Tandon V., Klutch R., Steiner B., Drain A.E., Shattuck D.W., Hull L., Wang H.J., Elashoff R.M., Swerdloff R.S., Voskuhl R.R. Testosterone treatment in multiple sclerosis: a pilot study. Arch. Neurol. 2007, 64:683-688.
57. Gold S.M., Chalifoux S., Giesser B.S., Voskuhl R.R. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J. Neuroinflammation 2008, 5:32.
58. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W., Sherman S., Sluss P.M., de Villiers T.J. Executive summary of the Stages of Reproductive Aging Workshop+10: addressing the unfinished agenda of staging reproductive aging. J. Clin. Endocrinol. Metab. 2012, 97:1159-1168.
59. Kato I., Toniolo P., Akhmedkhanov A., Koenig K.L., Shore R., Zeleniuch-Jacquotte A. Prospective study of factors influencing the onset of natural menopause. J. Clin. Epidemiol. 1998, 51:1271-1276.
60. Jacobsen B.K., Heuch I., Kvale G. Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am. J. Epidemiol. 2003, 157:923-929.
61. O'Connor K.A., Holman D.J., Wood J.W. Declining fecundity and ovarian ageing in natural fertility populations. Maturitas 1998, 30:127-136.
62. Burger H.G. Diagnostic role of follicle-stimulating hormone (FSH) measurements during the menopausal transition-an analysis of FSH, oestradiol and inhibin. Eur. J. Endocrinol. 1994, 130:38-42.
63. Ferrell R.J., O'Connor K.A., Rodriguez G., Gorrindo T., Holman D.J., Brindle E., Miller R.C., Schechter D.E., Korshalla L., Simon J.A., Mansfield P.K., Wood J.W., Weinstein M. Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in steroid hormones and menstrual cycle lengths with age. Menopause 2005, 12:567-577.
64. Ferrell R.J., Simon J.A., Pincus S.M., Rodriguez G., O'Connor K.A., Holman D.J., Weinstein M. The length of perimenopausal menstrual cycles increases later and to a greater degree than previously reported. Fertil. Steril. 2006, 86:619-624.
65. O'Connor K.A., Ferrell R.J., Brindle E., Shofer J., Holman D.J., Miller R.C., Schechter D.E., Singer B., Weinstein M. Total and unopposed estrogen exposure across stages of the transition to menopause. Cancer Epidemiol. Biomark. Prev. 2009, 18:828-836.
66. O'Connor K.A., Ferrell R., Brindle E., Trumble B., Shofer J., Holman D.J., Weinstein M. Progesterone and ovulation across stages of the transition to menopause. Menopause 2009, 16:1178-1187.
67. Davison S.L., Bell R., Donath S., Montalto J.G., Davis S.R. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J. Clin. Endocrinol. Metab. 2005, 90:3847-3853.
68. Aschheim P. Results provided by heterochronic grafts of the ovaries in the study of the hypothalamo-hypophyso-ovarian regulation of senile rats. Gerontologia 1964, 10:65-75.
69. Neal-Perry G., Nejat E., Dicken C. The neuroendocrine physiology of female reproductive aging: an update. Maturitas 2010, 67:34-38.
70. Shaw N.D., Srouji S.S., Histed S.N., McCurnin K.E., Hall J.E. Aging attenuates the pituitary response to gonadotropin-releasing hormone. J. Clin. Endocrinol. Metab. 2009, 94:3259-3264.
71. Hale G.E., Hughes C.L., Burger H.G., Robertson D.M., Fraser I.S. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause 2009, 16:50-59.
72. Klein N.A., Battaglia D.E., Fujimoto V.Y., Davis G.S., Bremner W.J., Soules M.R. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J. Clin. Endocrinol. Metab. 1996, 81:1038-1045.
73. Faas M., Bouman A., Moesa H., Heineman M.J., de Leij L., Schuiling G. The immune response during the luteal phase of the ovarian cycle: a Th2-type response?. Fertil. Steril. 2000, 74:1008-1013.
74. Shakhar K., Shakhar G., Rosenne E., Ben-Eliyahu S. Timing within the menstrual cycle, sex, and the use of oral contraceptives determine adrenergic suppression of NK cell activity. Br. J. Cancer 2000, 83:1630-1636.
75. White H.D., Crassi K.M., Givan A.L., Stern J.E., Gonzalez J.L., Memoli V.A., Green W.R., Wira C.R. CD3+ CD8+ CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause. J. Immunol. 1997, 158:3017-3027.
76. Weiskopf D., Weinberger B., Grubeck-Loebenstein B. The aging of the immune system. Transpl. Int. 2009, 22:1041-1050.
77. Gameiro C.M., Romao F., Castelo-Branco C. Menopause and aging: changes in the immune system-a review. Maturitas 2010, 67:316-320.
78. Gameiro C., Romao F. Changes in the immune system during menopause and aging. Front Biosci. (Elite Ed) 2010, 2:1299-1303.
79. Straub R.H., Hense H.W., Andus T., Scholmerich J., Riegger G.A., Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J. Clin. Endocrinol. Metab. 2000, 85:1340-1344.
80. Brooks-Asplund E.M., Tupper C.E., Daun J.M., Kenney W.L., Cannon J.G. Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women. Cytokine 2002, 19:193-200.
81. Blum M., Zacharovich D., Pery J., Kitai E. Lowering effect of estrogen replacement treatment on immunoglobulins in menopausal women. Rev. Fr. Gynecol. Obstet. 1990, 85:207-209.
82. Costenbader K.H., Feskanich D., Stampfer M.J., Karlson E.W. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007, 56:1251-1262.
83. Font J., Pallares L., Cervera R., Lopez-Soto A., Navarro M., Bosch X., Ingelmo M. Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Ann. Rheum. Dis. 1991, 50:702-705.
84. Boddaert J., Huong D.L., Amoura Z., Wechsler B., Godeau P., Piette J.C. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore) 2004, 83:348-359.
85. Ho C.T., Mok C.C., Lau C.S., Wong R.W. Late onset systemic lupus erythematosus in southern Chinese. Ann. Rheum. Dis. 1998, 57:437-440.
86. Namjou B., Scofield R.H., Kelly J.A., Goodmon E., Aberle T., Bruner G.R., Harley J.B. The effects of previous hysterectomy on lupus. Lupus 2009, 18:1000-1005.
87. Mok C.C., Lau C.S., Ho C.T., Wong R.W. Do flares of systemic lupus erythematosus decline after menopause?. Scand. J. Rheumatol. 1999, 28:357-362.
88. Sanchez-Guerrero J., Villegas A., Mendoza-Fuentes A., Romero-Diaz J., Moreno-Coutino G., Cravioto M.C. Disease activity during the premenopausal and postmenopausal periods in women with systemic lupus erythematosus. Am. J. Med. 2001, 111:464-468.
89. Urowitz M.B., Ibanez D., Jerome D., Gladman D.D. The effect of menopause on disease activity in systemic lupus erythematosus. J. Rheumatol. 2006, 33:2192-2198.
90. Fernandez M., Calvo-Alen J., Alarcon G.S., Roseman J.M., Bastian H.M., Fessler B.J., McGwin G., Vila L.M., Sanchez M.L., Reveille J.D. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. Arthritis Rheum. 2005, 52:1655-1664.
91. Mok C.C., Wong R.W., Lau C.S. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum. 1999, 42:1274-1280.
92. Cooper G.S., Dooley M.A., Treadwell E.L., St Clair E.W., Gilkeson G.S. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis Rheum. 2002, 46:1830-1839.
93. Meier C.R., Sturkenboom M.C., Cohen A.S., Jick H. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J. Rheumatol. 1998, 25:1515-1519.
94. Buyon J.P., Petri M.A., Kim M.Y., Kalunian K.C., Grossman J., Hahn B.H., Merrill J.T., Sammaritano L., Lockshin M., Alarcon G.S., Manzi S., Belmont H.M., Askanase A.D., Sigler L., Dooley M.A., Von Feldt J., McCune W.J., Friedman A., Wachs J., Cronin M., Hearth-Holmes M., Tan M., Licciardi F. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann. Intern. Med. 2005, 142:953-962.
95. Mok C.C., Lau C.S., Ho C.T., Lee K.W., Mok M.Y., Wong R.W. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand. J. Rheumatol. 1998, 27:342-346.
96. Arden N.K., Lloyd M.E., Spector T.D., Hughes G.R. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus 1994, 3:11-13.
97. Sanchez-Guerrero J., Gonzalez-Perez M., Durand-Carbajal M., Lara-Reyes P., Jimenez-Santana L., Romero-Diaz J., Cravioto M.D. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum. 2007, 56:3070-3079.
98. Bhattoa H.P., Bettembuk P., Balogh A., Szegedi G., Kiss E. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Osteoporos. Int. 2004, 15:396-404.
99. Goemaere S., Ackerman C., Goethals K., De Keyser F., Van der Straeten C., Verbruggen G., Mielants H., Veys E.M. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J. Rheumatol. 1990, 17:1620-1622.
100. Merlino L.A., Cerhan J.R., Criswell L.A., Mikuls T.R., Saag K.G. Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin. Arthritis Rheum. 2003, 33:72-82.
101. Pikwer M., Bergstrom U., Nilsson J.A., Jacobsson L., Turesson C. Early menopause is an independent predictor of rheumatoid arthritis. Ann. Rheum. Dis. 2012, 71:378-381.
102. Pikwer M., Nilsson J.A., Bergstrom U., Jacobsson L.T., Turesson C. Early menopause and severity of rheumatoid arthritis in women over 45years of age. Arthritis Res. Ther. 2012, 14:R190.
103. Turkcapar N., Demir O., Atli T., Kopuk M., Turgay M., Kinikli G., Duman M. Late onset rheumatoid arthritis: clinical and laboratory comparisons with younger onset patients. Arch. Gerontol. Geriatr. 2006, 42:225-231.
104. Deal C.L., Meenan R.F., Goldenberg D.L., Anderson J.J., Sack B., Pastan R.S., Cohen A.S. The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. Arthritis Rheum. 1985, 28:987-994.
105. Filipowicz-Sosnowska A., Rupinski R. Elderly onset rheumatoid arthritis. Pol. Arch. Med. Wewn. 2008, 118(Suppl.):36-42.
106. Kuiper S., van Gestel A.M., Swinkels H.L., de Boo T.M., da Silva J.A., van Riel P.L. Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis. J. Rheumatol. 2001, 28:1809-1816.
107. Walitt B., Pettinger M., Weinstein A., Katz J., Torner J., Wasko M.C., Howard B.V. Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. Arthritis Rheum. 2008, 59:302-310.
108. Hall G.M., Daniels M., Huskisson E.C., Spector T.D. A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann. Rheum. Dis. 1994, 53:112-116.
109. Karlson E.W., Mandl L.A., Hankinson S.E., Grodstein F. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses' Health Study. Arthritis Rheum. 2004, 50:3458-3467.
110. Hall G.M., Daniels M., Doyle D.V., Spector T.D. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. 1994, 37:1499-1505.
111. MacDonald A.G., Murphy E.A., Capell H.A., Bankowska U.Z., Ralston S.H. Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann. Rheum. Dis. 1994, 53:54-57.
112. D'Elia H.F., Larsen A., Mattsson L.A., Waltbrand E., Kvist G., Mellstrom D., Saxne T., Ohlsson C., Nordborg E., Carlsten H. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J. Rheumatol. 2003, 30:1456-1463.
113. Forsblad-d'Elia H., Carlsten H. Hormone replacement therapy in postmenopausal women with rheumatoid arthritis stabilises bone mineral density by digital x-ray radiogrammetry in a randomised controlled trial. Ann. Rheum. Dis. 2011, 70:1167-1168.
114. Paty D.W., Noseworthy J.H., Ebers G.C. Diagnosis of multiple sclerosis. Mult Scler 1997, 48-51. FA Davis Company, Philadelphia, PA. D.W. Paty, G.C. Ebers (Eds.).
115. Hooge J.P., Redekop W.K. Multiple sclerosis with very late onset. Neurology 1992, 42:1907-1910.
116. Kis B., Rumberg B., Berlit P. Clinical characteristics of patients with late-onset multiple sclerosis. J. Neurol. 2008, 255:697-702.
117. Tremlett H., Devonshire V. Is late-onset multiple sclerosis associated with a worse outcome?. Neurology 2006, 67:954-959.
118. Noseworthy J., Paty D., Wonnacott T., Feasby T., Ebers G. Multiple sclerosis after age 50. Neurology 1983, 33:1537-1544.
119. Bove R.M., Healy B., Augustine A., Musallam A., Gholipour T., Chitnis T. Effect of gender on late-onset multiple sclerosis. Mult. Scler. 2012, 18:1472-1479.
120. Filippi M., Wolinsky J.S., Sormani M.P., Comi G. Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis. Neurology 2001, 56:422-423.
121. Mowry E.M., Pesic M., Grimes B., Deen S., Bacchetti P., Waubant E. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology 2009, 72:602-608.
122. Holmqvist P., Wallberg M., Hammar M., Landtblom A.M., Brynhildsen J. Symptoms of multiple sclerosis in women in relation to sex steroid exposure. Maturitas 2006, 54:149-153.
123. Smith R., Studd J.W. A pilot study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and the menstrual cycle. J. R. Soc. Med. 1992, 85:612-613.
124. Wundes A., Amtmann D., Brown T., Christian S. Menopause in women with multiple sclerosis. Int. J. MS Care 2011, 13:47.
125. Sammaritano L.R. Menopause in patients with autoimmune diseases. Autoimmun. Rev. 2012, 11:A430-A436.